Browse the latest research summaries in the field of regenerative medicine for spinal cord injury patients and caregivers.
Showing 381-390 of 2,298 results
Frontiers in Neuroscience, 2022 • October 5, 2022
This systematic review and network meta-analysis of EVs derived from miRNA-modified MSCs for the treatment of SCI included data from 13 preclinical trials among a total of 396 rats. The results of this...
KEY FINDING: miRNA-overexpressing MSCs-derived EVs (100 and 200 µg of total protein of EVs) significantly improved hind limb motor function in rats at early stages of SCI (i.e., at 3 days after injury) as compared with EVs (100 and 200 µg of total protein of EVs, respectively).
Frontiers in Pharmacology, 2022 • October 19, 2022
Muse cells are endogenous pluripotent-like stem cells found in various tissues, exhibiting triploblastic differentiation, self-renewal, stress tolerance, and reparative function. They home to damaged ...
KEY FINDING: Muse cells selectively accumulate at damaged sites by sensing sphingosine-1-phosphate (S1P), a key mediator of inflammation.
Spine Surg Relat Res, 2022 • October 1, 2022
This systematic review and meta-analysis aimed to evaluate the efficacy of mesenchymal stem cell-derived conditioned media (MSC-CM) in promoting motor recovery following spinal cord injury (SCI) in an...
KEY FINDING: MSC-CM administration in SCI animal models promotes motor recovery, indicating a potential therapeutic effect. MSC-CM administration in SCI animal models promotes motor recovery
BMC Neuroscience, 2022 • November 4, 2022
This study investigates whether pre-conditioning adipose-derived stem cells (ADSCs) with melatonin (MT) can enhance their engraftment and neurological function in rats with spinal cord injury (SCI). T...
KEY FINDING: Melatonin pre-treatment increased the number of ADSCs that successfully implanted at the injury site.
Bioactive Materials, 2023 • January 1, 2023
This study developed an anisotropic Fe3S4 ferrofluid hydrogel (FFH) with sustained release of hydrogen sulfide (H2S) to address the limitations of spinal cord injury (SCI) repair. The FFH demonstrated...
KEY FINDING: Fe3S4 FFH significantly reduced inflammatory factors in LPS-induced BV2 cells in vitro, demonstrating its anti-inflammatory properties.
Front. Transplant., 2023 • December 7, 2023
This case report describes the functional recovery of a 41-year-old quadriplegic spinal cord injury patient following multiple intravenous infusions of autologous adipose-derived mesenchymal stem cell...
KEY FINDING: The patient experienced significant improvements in quality-of-life, as demonstrated by substantial improvements in SCIM-III scores.
Heliyon, 2024 • June 13, 2024
The study aimed to verify the analgesic effect of intravenous administration of human umbilical cord mesenchymal stem cells (HUC-MSCs) upon rats with chronic constriction injury (CCI)-induced neuropat...
KEY FINDING: Intravenous administration of HUC-MSCs significantly ameliorated CCI-induced mechanical allodynia and thermal hyperalgesia in rats.
Theranostics, 2022 • October 31, 2022
This study introduces a novel self-assembled peptide, Nap-E7-YIGSR, coated on aligned PCL fibers, designed to enhance neuronal differentiation of spermatogonial stem cells (SSCs) for spinal cord injur...
KEY FINDING: The Nap-E7-YIGSR peptide enhances the adhesion of SSCs to PCL fibers, improving the material's hydrophilicity and SSC affinity.
Frontiers in Cellular Neuroscience, 2022 • November 17, 2022
Spinal cord injury (SCI) presents a significant challenge due to neuronal death and dysfunction of non-neuronal cells. Current treatments offer limited recovery, highlighting the need for innovative t...
KEY FINDING: Fibroblasts, astrocytes, NG2 cells, and neural progenitor cells can be reprogrammed into neurons or oligodendrocytes to promote spinal cord repair.
Frontiers in Cellular Neuroscience, 2022 • November 23, 2022
This study aimed to modulate the inflammatory milieu in spinal cord injury (SCI) by using lipopolysaccharide (LPS) and granulocyte colony-stimulating factor (G-CSF) to improve bone-marrow mesenchymal ...
KEY FINDING: Medium-dose LPS administration resulted in a local anti-inflammatory beneficial role, associated with increased NF-200-positive cells, tissue sparing, and improved functional recovery.